The Zhitong Finance App learned that on December 19, the China Securities Regulatory Commission announced the disclosure of supplementary materials for overseas issuance and filing (December 15, 2025 to December 19, 2025). The Securities Regulatory Commission requested Jingfeng Medical to explain whether the reason why the company was unable to go public in Hong Kong after the application for listing in Hong Kong was approved by me in July 2022 constituted a substantial obstacle to the current listing in Hong Kong. According to the Hong Kong Stock Exchange's disclosure on January 11, 2023, Jingfeng Medical submitted to the Hong Kong Stock Exchange, with Morgan Stanley, CICC, and Citibank as co-sponsors.

Zhitongcaijing · 1d ago
The Zhitong Finance App learned that on December 19, the China Securities Regulatory Commission announced the disclosure of supplementary materials for overseas issuance and filing (December 15, 2025 to December 19, 2025). The Securities Regulatory Commission requested Jingfeng Medical to explain whether the reason why the company was unable to go public in Hong Kong after the application for listing in Hong Kong was approved by me in July 2022 constituted a substantial obstacle to the current listing in Hong Kong. According to the Hong Kong Stock Exchange's disclosure on January 11, 2023, Jingfeng Medical submitted to the Hong Kong Stock Exchange, with Morgan Stanley, CICC, and Citibank as co-sponsors.